{
    "links": "https://www.ycombinator.com/companies/olio-labs",
    "name": "Olio Labs",
    "headline": "Combination therapeutics for the world's toughest diseases",
    "batch": "S23",
    "description": "Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.",
    "activity_status": "Active",
    "website": "https://oliolabs.co/",
    "founded_date": 2023.0,
    "team_size": 5.0,
    "location": null,
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": null,
    "founders": [
        {
            "name": "David Tingley, Founder",
            "description": "David has over 13 years of experience as a systems neuroscientist and biologist. His interest in systems biology led him to earn a PhD in Neuroscience at New York University and complete postdoctoral research at Harvard. During this time, he published more than 15 scientific articles and uncovered a link between oscillations in brain activity and glucose metabolism in the body (Tingley et al., Nature 2020).",
            "linkedin": "https://linkedin.com/in/david-tingley-0428b5229"
        },
        {
            "name": "Tom Roseberry, Founder",
            "description": "Tom has over 15 years of industry experience leading teams and engineering technologies in aerospace, brain machine interfacing, synthetic biology and drug discovery/development. At Neuralink he built and co-led a group that developed a next-generation neural interface. At Loyal he built and led multiple teams as VP of Engineering, Computational Biology and Drug Development.",
            "linkedin": "https://linkedin.com/in/tom-roseberry-a84501163"
        }
    ],
    "status": true,
    "generated_description": "**Olio Labs** is a cutting-edge biotech company founded in 2023, currently a participant in the Y Combinator Batch S23. Its mission is straightforward yet ambitious: to tackle the world\u2019s toughest diseases through combination therapeutics that leverage the intricate network of proteins in our bodies.\n\n### The Science Behind Olio Labs\n\nUnlike traditional drug development that often targets a single protein or pathway, Olio Labs utilizes advanced AI to explore trillions of potential combinations. This approach is especially vital for complex conditions like obesity, where their lead therapeutic candidates aim to outperform current market leaders\u2014specifically, Ozempic, which is the fastest-growing drug in history. By focusing on multi-target strategies, Olio Labs promises not only increased efficacy but also a reduction in side effects, making their solutions more patient-friendly.\n\n### Team and Location\n\nBased in a currently unspecified location, the startup is lean but agile, with a dedicated team of five employees. This tight-knit group is committed to transforming the therapeutic landscape through the power of machine learning and innovative biochemistry.\n\n### Looking Ahead\n\nAs Olio Labs continues its journey, its bold integration of real-world data and cutting-edge technology positions it at the forefront of precision medicine. The company\u2019s pioneering work could redefine treatment protocols for some of the most challenging health issues we face today. \n\nIf you\u2019re curious to learn more or follow their progress, you can visit their website at [Olio Labs](https://oliolabs.co/). \n\nIn the rapidly evolving field of biotech, Olio Labs is strikingly positioned to make a significant impact\u2014keep an eye on them.",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/12c8dc0770b7bd797e488ca2efb3a6afcc27b4d7.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAJMV6TLGB%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191608Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJGMEQCIFLa1ybFb1MW3YWarl6N2DZLtQ4R6h64JtRzg2nxAowaAiB3nTk9Wj2wgaQBuQdmXKSYUK01s%2FfzNcIsI%2FpnnVYrDCruAwjc%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAAaDDAwNjIwMTgxMTA3MiIMbK4eHGyZbeOmKiEOKsIDEgeFqYzoIm9WYPES%2BanLfTcQEGyzIks%2Fal2Lmqxe4p56ewXYsETQE6xKLCXrmvzZNyUDpx5dtkyRoWAO6FYyXXGaPQzEZ3lyFdj%2BxmzYPjn73zyfO0POWT06n60Ss4FWi%2BsXTCqzCDlztmj5P3pe%2BccFf3AJ6Fob0iUEcgWZg86XqS2niw4lXPnalb%2Boq3NuXvHl2oVLzjcW3kqbNIZD4bJeuP%2BaiX3YtJ%2BJXjqRV4JMYzbegC89ld8%2FQ6Niu9GP6iWyA3Ij%2Frc6v9eF94GLnVFmDUIq%2FgOldm3US8WLOYW64cbfEYgRv4%2BZqFOZik7gMqvr0%2BAMO66zctStkeS7pQEndome2HMXzolZnAHIKHa7syJwRucmMBn1qLVqGHDFwDTWD66ZqASdClXaJEb6qKYFGBQM0HPz9IZYPkFD7FlZyifcWNrFEjlM4LJiyAQcunx30b5EMcz8oT7YjYIo5Bb2DOsnIt6uAdkOmUPUmY%2FzM3PmuL6ZYePw7XBzfBYcfiNqZPHWFO6x0%2FmP5sl5TFTspcBFiC1tU5q9L40pvlUpeAHA0lByHoziRM9b9aIUnBzO8cEmGGLYvEv9AlDEIduUMLKL470GOqYBeuzvU%2B1K1xvzamOk1TaDeko%2BJlQ8xUgcguCKvnE%2BpYSn9MQz0SIXrm4hUrSnIO%2FjFoTZ4esBSlXTCkXH%2F6%2BRHttOAoEAfv1XQWO8%2Bsv2qVS97SrODEBLVhY1tfEFQcw%2BZ93GUo5LYHe1U2PubGkf9wTLJ5AZCq5Vr1%2FKLwVlulVfHEhtz4E3fzOL1TPO7tIclZor0kZmzjAwtkky7VHrQVXehNV3Gw%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=592a0bfa6af1b414e30fd90c95209774e58ceb87df93f5566fde63f24d233f49",
    "social_links": [
        "https://www.linkedin.com/company/olio-labs/?viewAsMember=true",
        "https://github.com/Olio-Labs/olio"
    ],
    "logo_path": "data/logos\\Olio_Labs_logo.png"
}